October 3rd 2023
Liquid biopsy is offering a noninvasive, real-time, and personalized approach to tumor assessment, and is already revolutionizing the field of clinical oncology.
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Liquid Biopsy Shows Potential for Predicting Survival Outcomes in TNBC
March 1st 2018According to results from a retrospective study published in the <em>Journal of Clinical Oncology, </em>low-coverage genome-wide sequencing of cell-free DNA from plasma is capable of profiling cancer genomes from blood and predicting survival outcomes for patients with metastatic triple-negative breast cancer.
Read More
Blood-Based Liquid Biopsy Demonstrates 88% Accuracy in Detecting Colorectal Cancers Early
January 17th 2018A novel circulating tumor cell assay has demonstrated a high accuracy of up to 88% for detecting early-stage colorectal cancer, according to the results of a prospective study from Taiwan released ahead of a presentation at the 2018 Gastrointestinal Cancers Symposium in San Francisco, California. The study marks the first to show a high sensitivity for detecting precancerous lesions, as prior studies tended to identify later-stage CRCs.
Read More
PFS Benefit in NSCLC Immunotherapy Predicted With Liquid Biopsy for Mutation Burden
September 10th 2017According to a retrospective analysis of a randomized study presented at the 2017 ESMO Congress, a liquid biopsy that measures tumor mutational burden showed promise for predicting benefit in patients with non–small cell lung cancer treated with a checkpoint inhibitor.
Read More
A new, high-intensity genomic sequencing approach for circulating tumor DNA uncovered at least 1 genetic change in both the tumor DNA and the blood of 89% of patients, demonstrating a high rate of concordance between 2 approaches for detecting molecular aberrations, according to a study presented at the 2017 ASCO Annual Meeting.
Read More
Liquid Biopsy Analysis of FGFR3 and PIK3CA for Disease Surveillance in Bladder Cancer
April 21st 2017Emil Christensen, PhD candidate, Aarhus University Hospital, Denmark, discusses a liquid biopsy analysis of <em>FGFR3</em> and <em>PIK3CA</em> hotspot mutations for disease surveillance in bladder cancer.
Watch
Liquid Biopsies Likely to Play Important Role in Management of NSCLC
August 25th 2016The optimal use of emerging assays that characterize molecular abnormalities from plasma in late-stage non-small cell lung cancer will be to augment tissue biopsies at initial diagnosis and to evaluate patients for second- and third-line therapies.
Read More
The Role of Plasma as a Potential Alternative to EGFR Mutation Analysis in NSCLC
August 4th 2016Nicola Normanno, MD, chief of the Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Naples, Italy, discusses the recent data showing that plasma can act as a potential alternative to EGFR mutation analysis in the treatment of patients with non-small cell lung cancer, as well as the current demands for the use of liquid biopsies in this type of treatment.
Watch
Largest-Ever Liquid Biopsy Study Increases Favor for Mutation Testing Method
June 9th 2016The liquid biopsy testing method from a large genomic analysis of circulating tumor DNA (ctDNA) in blood samples from more than 15,000 patients, was found to be closely correlated with mutations described in databases, and often from tumor biopsies as well, according to research presented at the 2016 ASCO Annual Meeting.
Read More
Liquid Biopsy Further Expands Prostate Cancer Treatment Armamentarium
January 5th 2016Resistance to androgen receptor therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) has historically posed a challenge to clinicians. Now, a new blood test that analyzes circulating tumor cells (CTCs) could help overcoming these hurdles.
Read More
Early Detection of Resistance in Lung Cancer Detected Through ctDNA in Urine
June 17th 2015An assay that measures circulating tumor (ct) DNA in the urine can detect the early acquisition of epidermal growth factor receptor (EGFR) resistance mutations in patients with metastatic lung adenocarcinoma.
Read More
Clinical Validation and Utility of a Liquid Biopsy in NSCLC
June 11th 2015Veena Singh, MD, senior vice president and senior medical director, Biocept, Inc., discusses the clinical validation and utility of a liquid biopsy in non-small cell lung cancer (NSCLC) using circulating tumor cells (CTCs) and ctDNA to analyze EGFR, ALK and ROS status.
Read More
Liquid Biopsies Detect Minimal Residual Disease in Colorectal Cancer
April 29th 2015Two different types of liquid biopsies—plasma and urine—can detect the number of copies of the KRAS mutation in circulating DNA in patients with colorectal cancer who have resectable liver metastases with near 100% concordance with tissue biopsies, according to a pilot study presented at the 2015 Annual Meeting of the American Association for Cancer Research (AACR).
Read More
Neoantigens for Personalized Immunotherapy May Boost Melanoma Treatment
April 17th 2015Abnormal driver mutations contribute to tumor progression and have been prime targets for many therapeutic studies in oncology; however, researchers are focusing more and more on the less-studied passenger mutations and their role in tumor progression.
Read More
Liquid Biopsy Use in NSCLC Clinical Practice on the Horizon
February 25th 2015The definition of liquid biopsy has expanded to include the collection of cfDNA, along with various species of cell-free RNA and exosomes, all of which are capable of providing information on the disease status of cancer patients.
Read More
High Levels of KRAS in ctDNA of Pancreatic Cancer May Mean Lower OS
January 21st 2015During a retrospective study of 182 patients with nonresectable pancreatic cancer, a negative association was found between baseline circulating tumor (ct)DNA KRAS counts in plasma and overall survival (OS), which indicates that patients with lower KRAS burden in ctDNA survive longer.
Read More
Biomarker Analysis of GIST Tumors Suggests New Potential for Old Treatments
January 21st 2015Researchers for Caris Life Sciences have used the company's proprietary tumor profiling platform to identify biomarkers in GIST that may be used to identify more effective therapeutic regimens for individuals with TKI-resistant GIST.
Read More
Cell-Free DNA Detection in Histiocytic Disorders May Transform Diagnosis and Treatment
January 8th 2015Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) are characterized by a high frequency of BRAFV600E mutations, which are responsive to treatment with BRAF inhibitors such as vemurafenib.
Read More